Payload Information

General Information of This Payload
Payload ID
PAY0KYMRL
Name
Dexamethasone
Synonyms
Dexamethasone; 50-02-2; Decadron; Maxidex; Dexamethazone; Hexadecadrol; Millicorten; Decaspray; Dexasone; Hexadrol; Oradexon; Prednisolone F; Aeroseb-Dex; Fluormethylprednisolone; Desametasone; Superprednol; Visumetazone; Cortisumman; Decaderm; Dexacortal; Dexacortin; Fortecortin; Gammacorten; Auxiron; Calonat; Dexason; Dexone; Azium; Aphtasolon; Dectancyl; Deltafluorene; Dergramin; Desadrene; Desamethasone; Desameton; Dexadeltone; Dexapolcort; Mediamethasone; Mymethasone; Corsone; Decalix; Decasone; Dekacort; Dexacort; Dexalona; Dexameth; Dextelan; Dinormon; Loverine; Luxazone; Mexidex; Dexa-Cortidelt; Dexa-Scheroson; Dexa-Cortisyl; Prednisolon F; Dexa-sine; Isopto-Dex; SK-Dexamethasone; Aeroseb-D; Anaflogistico; Decacortin; Deseronil; Dexafarma; Dexaprol; Dexinolon; Dexinoral; Policort; Spoloven; Turbinaire; Deronil; Dexapos; Sunia Sol D; Bisu DS; Dexa Mamallet; Lokalison F; Ocu-trol; Dex-ide; Hl-dex; Dexamethasonum; Decameth; Fluormone; Fluorocort; Decagel; Dexpak; Dezone; Dexone 4; Dxms; Hexadrol Elixir; Pet Derm III; Dexamethasone alcohol; Dexamethasone Intensol; Methylfluorprednisolone; Dexone 0.5; Dexone 1.5; Dexametasona; Decaject; Dexone 0.75; Hexadrol Tablets; Desametasone [DCIT]; Aphthasolone; Decacort; Dexamonozon; Dextenza; Ozurdex; 9alpha-Fluoro-16alpha-methylprednisolone; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Decadron Tablets, Elixir; Decaject-L.A.; Azium (Veterinary); Dexametasone; Dexamethansone; MK 125; Adexone; Dexaltin; Osurdex; Posurdex; Dexycu; Prodex; DexaSite; OTO-104; Dexa-Mamallet; Corson; NSC 34521; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoroprednisolone; (3H)-Dexamethasone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; Azimycin (Veterinary); delta1-9alpha-Fluoro-16alpha-methylcortisol; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; Naquasone (Veterinary); Tresaderm (Veterinary); CCRIS 7067; Dexonium; Diodex; DTXSID3020384; HSDB 3053; ISV-305; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; Zema-Pak; UNII-7S5I7G3JQL; Dexamethasone Base; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; EINECS 200-003-9; 7S5I7G3JQL; MFCD00064136; NSC-34521; Decadron (TN); 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; DXM [Steroid]; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; HEMADY; Dexamethasone [INN:BAN:JAN]; Dexamethasone (GMP); Dexamethasone, topical; CHEBI:41879; AI3-50934; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; Prednisolone, 9alpha-fluoro-16alpha-methyl-; C22H29FO5; (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Dexamethasone (DHAP); dexmethsone; DTXCID10384; MLS001332507; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; Dexamethasone [USP:INN:BAN:JAN]; DXM (Steroid); 9-Fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; [3H]-dexamethasone; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-; CIPRODEX COMPONENT DEXAMETHASONE; MAXITROL COMPONENT DEXAMETHASONE; TOBRADEX COMPONENT DEXAMETHASONE; (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; DEXACIDIN COMPONENT DEXAMETHASONE; DEXASPORIN COMPONENT DEXAMETHASONE; DEXAMETHASONE COMPONENT OF CIPRODEX; DEXAMETHASONE COMPONENT OF MAXITROL; DEXAMETHASONE COMPONENT OF TOBRADEX; TOBRADEX ST COMPONENT DEXAMETHASONE; DEXAMETHASONE COMPONENT OF DEXACIDIN; DEXAMETHASONE COMPONENT OF DEXASPORIN; DEXAMETHASONE COMPONENT OF TOBRADEX ST; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 16-alpha-Methyl-9-alpha-fluoro-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 16-alpha-Methyl-9-alpha-fluoro-11-beta,17-alpha,21-trihydroxypregna-1,4-diene-3,20-dione; 4-alpha-Fluoro-16-alpha-methyl-11-beta,17,21-trihydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-methyl-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; DEXAMETHASONE (MART.); DEXAMETHASONE [MART.]; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 1-Dehydro-16-alpha-methyl-9-alpha-fluorohydrocortisone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; IontoDex; DEXAMETHASONE (EP MONOGRAPH); DEXAMETHASONE [EP MONOGRAPH]; DEXAMETHASONE (USP MONOGRAPH); DEXAMETHASONE [USP MONOGRAPH]; Pet-Derm Iii; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16alpha-methyl-; Decaject L.A.; (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione labeled with tritium; 23495-06-9; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, labeled with tritium, (11beta,16alpha)-; SMR000857119; BETAMETHASONE IMPURITY A (EP IMPURITY); BETAMETHASONE IMPURITY A [EP IMPURITY]; dexamethasone (tetramethyl-rhodamine conjugated ); Prednisolone, 9.alpha.-fluoro-16.alpha.-methyl-; Amplidermis; Auricularum; Cortidexason; Dexafluorene; Dexamecortin; Fluorodelta; Aacidexam; Baycadron; Decadrol; Dexalocal; Dexasine; Solurex; Spersadex; .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol; 16.alpha.-Methyl-9.alpha.-fluoro-.delta.(sup1)-hydrocortisone; Dxevo; NSC34521; TaperDex; Aknichthol Dexa; Alin Oftalmico; Anemul mono; Dexa-Rhinosan; .gamma.corten; ZoDex; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Alin Depot; Baycuten N; C22-H29-F-O5; Lokalison-F; Apo-dexamethasone; Decadron DP; Dexasone 4mg; Alba-Dex; PHL-dexamethasone; PMS-dexamethasone; [3H]dexamethasone; Decasone R.p.; Dexamethasone-omega; NCGC00091019-08; Dexasone 0.5mg; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.alpha.)-; Dexasone 0.75mg; Sandoz Dexamethasone; DEXASCHEROSON; DEXYCU KIT; Maxidex Ont 0.1%; Maxidex Sus 0.1%; Decadron, Dexamethasone; dexamethasone-17-acetate; Spectrum5_002019; DEXAMETHASONE [MI]; D0IT2G; Foy Brand of Dexamethasone; MolMap_000018; DEXAMETHASONE [INN]; DEXAMETHASONE [JAN]; ECR Brand of Dexamethasone; ICN Brand of Dexamethasone; SCHEMBL3774; Alcon Brand of Dexamethasone; DEXAMETHASONE [HSDB]; Merck Brand of Dexamethasone; BIDD:PXR0060; BSPBio_000995; DEXAMETHASONE [VANDF]; MLS001055412; MLS001332508; BIDD:ER0494; sustained-release dexamethasone; DEXAMETHASONE [USP-RS]; DEXAMETHASONE [WHO-DD]; DEXAMETHASONE [WHO-IP]; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; 3,20-DIONE; CHEMBL384467; Dexamethasone [BAN:INN:JAN]; GTPL2768; GTPL3447; SGCUT00126; 9-Fluoro-16-methylprednisolone; Ak Dex Oph Otic Soln 0.1%; DEXAMETHASONE [EMA EPAR]; BDBM18207; Dexamethasone (anti-inflammatory); Dexamethasone (JP15/USP/INN); Dexamethasone (JP17/USP/INN); (11-beta,16-alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 1p93; DEXAMETHASONE [GREEN BOOK]; HMS1792A17; HMS1990A17; HMS2089N13; HMS2235F08; HMS3039L11; HMS3259N11; HMS3403A17; DEXAMETHASONE [ORANGE BOOK]; AMY28815; DRG-0013; to_000038; Tox21_200122; Dexamethasone, >=97.0% (HPLC); HB2521; HY-14648G; IBI-10090; MK-125; s1322; Dexamethasone 1.0 mg/ml in Methanol; DEXAMETHASONUM [WHO-IP LATIN]; PMS Dexamethasone Elixir 0.5mg/5ml; AKOS005259009; AKOS015895509; Decadron phosphate, Decdan, Dexacort,; CCG-264887; CS-1505; CS-O-00294; CS-O-01282; CS-O-01283; DB01234; KS-1451; LS-7300; NC00645; alpha -Fluoro-16-alpha -methylcortisol; CAS-50-02-2; SMP1_000092; Dexamethasone, >=98% (HPLC), powder; NCGC00091019-01; NCGC00091019-02; NCGC00091019-03; NCGC00091019-04; NCGC00091019-05; NCGC00091019-06; NCGC00091019-07; NCGC00091019-23; NCGC00257676-01; (8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]ph; 9alpha-fluoro-16alpha-methyl-Prednisolone; AC-11056; HY-14648; NCI60_003067; SMR001227192; Fluoro-9alpha Methyl-16alpha Prednisolone; 16alpha -Methyl-9alpha -fluoroprednisolone; 9alpha -Fluoro-16alpha -methylprednisolone; Dexamethasone, tested according to Ph.Eur.; CS-0626118; EN300-52607; D00292; Dexamethasone, meets USP testing specifications; Prednisolone, 9alpha -fluoro-16alpha -methyl-; 9.alpha.-Fluoro-16.alpha.-methyl-1,20-dione; AB00918428-05; AB00918428-08; AB00918428-09; AB00918428_10; 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol; 16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone; Dexamethasone, VETRANAL(TM), analytical standard; Q422252; 1-Dehydro-16alpha-methyl-0alpha-fluorohydrocortisone; delta(Sup1)-9-alpha-fluoro-16-alpha-methylcortisol; Q-200939; 16-alpha-methyl-9-alpha-fluoro-delta-1-hydrocortisone; BRD-K38775274-001-02-3; BRD-K38775274-001-06-4; DEXAMETHASONE ACETATE IMPURITY A [EP IMPURITY]; 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone; 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione; Dexamethasone, British Pharmacopoeia (BP) Assay Standard; Z756391748; Pregna-1,4-diene-3,20-dione, 9-fluoro-11alpha -methyl-; Dexamethasone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1; 16-ALPHA-METHYL-9-ALPHA-FLUORO-DELTA(SUP 1)HYDROCORTISONE; Dexamethasone, powder, BioReagent, suitable for cell culture, >=97%; Dexamethasone, United States Pharmacopeia (USP) Reference Standard; 16-.alpha.-Methyl-9-.alpha.-fluoro-1,17-.alpha.,21-triol-3,20-dione; 4.alpha.-Fluoro-16.alpha.-methyl-11.beta.-17,4-diene-3,20-dione; Pregna-1,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl-; 16.alpha.-Methyl-9.alpha.-fluoro-11.beta.-17.alpha.-21-trihydroxypregna-1,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11.beta.,21-trihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione; 9-fluoro-16alpha-methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.-17.alpha.- 21-trihydroxy-16.alpha.-methylpregna-1,20-dione; Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard; Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard; Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material; Dexamethasone, powder, gamma-irradiated, BioXtra, suita
   Click to Show/Hide
Target(s) Glucocorticoid receptor (NR3C1)
 Target Info 
Structure
Formula
C22H29FO5
Isosmiles
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
PubChem CID
5743
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
InChIKey
UREBDLICKHMUKA-CXSFZGCWSA-N
IUPAC Name
(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Pharmaceutical Properties
Molecule Weight
392.5
Polar area
94.8
Complexity
805
xlogp Value
1.9
Heavy Count
28
Rot Bonds
2
Hbond acc
6
Hbond Donor
3
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Inhibitory Concentration (IC50) 0.016 ug/mL
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.165 ug/mL
J774.A1 cells
Mouse reticulum cell sarcoma
CVCL_0358 
[1]
Half Maximal Inhibitory Concentration (IC50) 1.84 ug/mL
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[1]
Half Maximal Inhibitory Concentration (IC50) >25 ug/mL
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[2]
Half Maximal Inhibitory Concentration (IC50) 36 ug/mL
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[2]
Half Maximal Inhibitory Concentration (IC50) 9.09 ug/mL
J774.A1 cells
Mouse reticulum cell sarcoma
CVCL_0358 
[1]
Half Maximal Effective Concentration (EC50) 0.2 nM
CV-1 cells
Normal
CVCL_0229 
[3]
Half Maximal Effective Concentration (EC50) 0.47 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Effective Concentration (EC50) 0.5 nM
Human foreskin fibroblasts cells
Normal
Undisclosed [5]
Half Maximal Inhibitory Concentration (IC50) 0.5082 nM
U2OS cells
Osteosarcoma
CVCL_0042 
[6]
Half Maximal Effective Concentration (EC50) 0.92 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Effective Concentration (EC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[7]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[8]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[9]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[10]
Half Maximal Inhibitory Concentration (IC50) 1 nM
Human foreskin fibroblasts cells
Normal
Undisclosed [11]
Half Maximal Effective Concentration (EC50) 1 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 1 nM
Splenocyte cells
Normal
Undisclosed [12]
Half Maximal Effective Concentration (EC50) 1.1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[13]
Half Maximal Effective Concentration (EC50) 1.1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[14]
Half Maximal Effective Concentration (EC50) 1.1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[15]
Half Maximal Effective Concentration (EC50) 1.1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[16]
Half Maximal Inhibitory Concentration (IC50) 1.175 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Effective Concentration (EC50) 1.2 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 1.259 nM
INS-1 832/13 cells
Rat insulinoma
CVCL_7226 
[18]
Half Maximal Effective Concentration (EC50) 1.3 nM
HEK293 cells
Normal
CVCL_0045 
[19]
Half Maximal Inhibitory Concentration (IC50) 1.585 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[20]
Half Maximal Inhibitory Concentration (IC50) 1.585 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[21]
Half Maximal Inhibitory Concentration (IC50) 1.8 nM
SW1353 cells
Bone chondrosarcoma
CVCL_0543 
[22]
Half Maximal Effective Concentration (EC50) 1.9 nM
Human foreskin fibroblasts cells
Normal
Undisclosed [23]
Half Maximal Effective Concentration (EC50) 1.9 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Effective Concentration (EC50) 1.995 nM
INS-1 832/13 cells
Rat insulinoma
CVCL_7226 
[24]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[25]
Half Maximal Effective Concentration (EC50) 10 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 10 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[26]
Half Maximal Inhibitory Concentration (IC50) 10 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[27]
Half Maximal Inhibitory Concentration (IC50) 10 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[28]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[8]
Half Maximal Inhibitory Concentration (IC50) >1000 nM
Sf9 cells
Normal
CVCL_0549 
[20]
Half Maximal Inhibitory Concentration (IC50) >1000 nM
Sf9 cells
Normal
CVCL_0549 
[20]
Half Maximal Inhibitory Concentration (IC50) >1000 nM
Sf9 cells
Normal
CVCL_0549 
[20]
Half Maximal Inhibitory Concentration (IC50) <10000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[29]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[25]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
THP-1 cells
Childhood acute monocytic leukemia
CVCL_0006 
[30]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
Caki-1 cells
Clear cell renal cell carcinoma
CVCL_0234 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SK-MEL-5 cells
Cutaneous melanoma
CVCL_0527 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SNB-19 cells
Astrocytoma
CVCL_0535 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
CVCL_1304 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
NCI-H226 cells
Pleural epithelioid mesothelioma
CVCL_1544 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
NCI-H322M cells
Minimally invasive lung adenocarcinoma
CVCL_1557 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
OVCAR-5 cells
Ovarian serous adenocarcinoma
CVCL_1628 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
OVCAR-8 cells
High grade ovarian serous adenocarcinoma
CVCL_1629 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SNB-75 cells
Glioblastoma
CVCL_1706 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SF268 cells
Astrocytoma
CVCL_1689 
[25]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
Multiple myeloma cancer stem cells
Multiple myeloma
Undisclosed [31]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
ACHN cells
Renal adenocarcinoma
CVCL_1067 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
HOP-92 cells
Non-small cell lung carcinoma
CVCL_1286 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
KM12 cells
Colon adenocarcinoma
CVCL_1331 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
M14 cells
Melanoma
CVCL_1395 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
Malme-3M cells
Melanoma
CVCL_1438 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
NCI-H522 cells
Non-small cell lung carcinoma
CVCL_1567 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
OVCAR-4 cells
Ovarian adenocarcinoma
CVCL_1627 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SF-295 cells
Glioblastoma
CVCL_1690 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
TK-10 cells
Renal carcinoma
CVCL_1773 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
UACC-257 cells
Melanoma
CVCL_1779 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
UACC-62 cells
Melanoma
CVCL_1780 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
UO-31 cells
Renal carcinoma
CVCL_1911 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
XF498 cells
Glioma
CVCL_8928 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
SNB-78 cells
Glioblastoma
CVCL_B321 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
M19-MEL cells
Melanoma
CVCL_B415 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
LXFL 529 cells
Non-small cell lung carcinoma
CVCL_D085 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 100000 nM
KM-20L2 cells
Colon carcinoma
CVCL_D889 
[25]
Half Maximal Inhibitory Concentration (IC50) 10700 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[32]
Half Maximal Inhibitory Concentration (IC50) 12.59 nM
Sf9 cells
Normal
CVCL_0549 
[20]
Half Maximal Inhibitory Concentration (IC50) 1200 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[33]
Half Maximal Effective Concentration (EC50) 130 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 130 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[34]
Half Maximal Inhibitory Concentration (IC50) 134 nM
Macrophage cells
Normal
Undisclosed [35]
Half Maximal Inhibitory Concentration (IC50) 137400 nM
Sf21 cells
Normal
CVCL_0518 
[36]
Half Maximal Effective Concentration (EC50) 14 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 1430 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[37]
Half Maximal Inhibitory Concentration (IC50) 14750 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[38]
Half Maximal Inhibitory Concentration (IC50) 150 nM
Peritoneal macrophage cells
Normal
Undisclosed [39]
Half Maximal Inhibitory Concentration (IC50) >15000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[40]
Half Maximal Inhibitory Concentration (IC50) >15000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[40]
Half Maximal Inhibitory Concentration (IC50) >15000 nM
Fibroblast cells
Normal
Undisclosed [40]
Half Maximal Effective Concentration (EC50) <15848.93 nM
U2OS cells
Osteosarcoma
CVCL_0042 
[6]
Half Maximal Inhibitory Concentration (IC50) 159200 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[41]
Half Maximal Inhibitory Concentration (IC50) 159200 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[42]
Half Maximal Inhibitory Concentration (IC50) 1600 nM
T-cells
Normal
Undisclosed [43]
Half Maximal Inhibitory Concentration (IC50) 169500 nM
J774 cells
Mouse reticulum cell sarcoma
CVCL_4692 
[44]
Half Maximal Effective Concentration (EC50) 17 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[23]
Half Maximal Effective Concentration (EC50) 17 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[45]
Half Maximal Effective Concentration (EC50) 17 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[46]
Half Maximal Inhibitory Concentration (IC50) 17 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [47]
Half Maximal Inhibitory Concentration (IC50) 170000 nM
J774.1 cells
Reticulum cell sarcoma
CVCL_4770 
[48]
Half Maximal Inhibitory Concentration (IC50) 18400 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[49]
Half Maximal Inhibitory Concentration (IC50) >19952.62 nM
Vero C1008 cells
Normal
CVCL_0574 
[50]
Half Maximal Effective Concentration (EC50) 2 nM
Human foreskin fibroblasts cells
Normal
Undisclosed [5]
Half Maximal Inhibitory Concentration (IC50) 2 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [51]
Half Maximal Effective Concentration (EC50) 2.1 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 2.3 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [52]
Half Maximal Effective Concentration (EC50) 2.4 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Effective Concentration (EC50) 2.5 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[13]
Half Maximal Effective Concentration (EC50) 2.5 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[14]
Half Maximal Effective Concentration (EC50) 2.5 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[15]
Half Maximal Effective Concentration (EC50) 2.5 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[16]
Half Maximal Effective Concentration (EC50) 2.5 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[53]
Half Maximal Inhibitory Concentration (IC50) 2.512 nM
THP-1 cells
Childhood acute monocytic leukemia
CVCL_0006 
[20]
Half Maximal Inhibitory Concentration (IC50) 2.512 nM
THP-1 cells
Childhood acute monocytic leukemia
CVCL_0006 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[54]
Half Maximal Inhibitory Concentration (IC50) 20 nM
RAW cells
Monocytic-macrophage leukemia
Undisclosed [55]
Half Maximal Inhibitory Concentration (IC50) 20 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[56]
Half Maximal Effective Concentration (EC50) >200 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
B16-F10 cells
Mouse melanoma
CVCL_0159 
[40]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
HEK-293T cells
Normal
CVCL_0063 
[40]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
CHO cells
Normal
CVCL_0213 
[40]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
Vero C1008 cells
Normal
CVCL_0574 
[50]
Half Maximal Inhibitory Concentration (IC50) 22000 nM
J774.A1 cells
Mouse reticulum cell sarcoma
CVCL_0358 
[57]
Half Maximal Inhibitory Concentration (IC50) 22200 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 23.93 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[25]
Half Maximal Inhibitory Concentration (IC50) 231900 nM
Sf21 cells
Normal
CVCL_0518 
[36]
Half Maximal Inhibitory Concentration (IC50) 24300 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[59]
Half Maximal Inhibitory Concentration (IC50) 25 nM
BV-2 cells
Normal
CVCL_0182 
[60]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[61]
Half Maximal Effective Concentration (EC50) 2600 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[62]
Half Maximal Inhibitory Concentration (IC50) 2660 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[63]
Half Maximal Effective Concentration (EC50) 3.162 nM
INS-1 832/13 cells
Rat insulinoma
CVCL_7226 
[18]
Half Maximal Effective Concentration (EC50) 3.5 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Effective Concentration (EC50) 3.6 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 3.6 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [64]
Half Maximal Inhibitory Concentration (IC50) 3.8 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [52]
Half Maximal Inhibitory Concentration (IC50) 3.8 nM
IM-9 cells
Multiple myeloma
CVCL_1305 
[65]
Half Maximal Inhibitory Concentration (IC50) 3.8 nM
IM-9 cells
Multiple myeloma
CVCL_1305 
[66]
Half Maximal Inhibitory Concentration (IC50) 3.981 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[10]
Half Maximal Effective Concentration (EC50) 30 nM
Farage cells
Normal
CVCL_0214 
[67]
Half Maximal Inhibitory Concentration (IC50) 32500 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[68]
Half Maximal Inhibitory Concentration (IC50) 355140 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[69]
Half Maximal Effective Concentration (EC50) 4.1 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 4.1 nM
HeLa S3 cells
Endocervical adenocarcinoma
CVCL_0058 
[70]
Half Maximal Effective Concentration (EC50) 4.2 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[15]
Half Maximal Effective Concentration (EC50) 4.2 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[53]
Half Maximal Effective Concentration (EC50) 4.2 nM
NP1 cells
Normal
CVCL_A9SL 
[13]
Half Maximal Inhibitory Concentration (IC50) 4.3 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [52]
Half Maximal Effective Concentration (EC50) 4.5 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[14]
Half Maximal Effective Concentration (EC50) 4.5 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[16]
Half Maximal Inhibitory Concentration (IC50) 4.6 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [52]
Half Maximal Inhibitory Concentration (IC50) 40 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[57]
Half Maximal Inhibitory Concentration (IC50) 400 nM
J774.A1 cells
Mouse reticulum cell sarcoma
CVCL_0358 
[57]
Half Maximal Inhibitory Concentration (IC50) 4160 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[71]
Half Maximal Inhibitory Concentration (IC50) 420 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[72]
Half Maximal Inhibitory Concentration (IC50) 4620580 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[73]
Half Maximal Inhibitory Concentration (IC50) 4620580 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[73]
Half Maximal Inhibitory Concentration (IC50) 470 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[74]
Half Maximal Inhibitory Concentration (IC50) 4700 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[57]
Half Maximal Inhibitory Concentration (IC50) 48 nM
J774.A1 cells
Mouse reticulum cell sarcoma
CVCL_0358 
[75]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 49317.38 nM
SR cells
Leukemia
CVCL_1711 
[25]
Half Maximal Inhibitory Concentration (IC50) 5 nM
T-cells
Normal
Undisclosed [76]
Half Maximal Inhibitory Concentration (IC50) 5 nM
R1 cells
Normal
CVCL_2167 
[77]
Half Maximal Effective Concentration (EC50) 5.012 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Effective Concentration (EC50) 5.37 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[8]
Half Maximal Effective Concentration (EC50) 5.5 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 50 nM
THP-1 cells
Childhood acute monocytic leukemia
CVCL_0006 
[30]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
LLC-PK1 cells
Normal
CVCL_0391 
[78]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
LLC-PK1 cells
Normal
CVCL_0391 
[78]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
LLC-PK1 cells
Normal
CVCL_0391 
[78]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[73]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[73]
Half Maximal Inhibitory Concentration (IC50) >500000 nM
HEK293 cells
Normal
CVCL_0045 
[79]
Half Maximal Inhibitory Concentration (IC50) 5020 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[41]
Half Maximal Inhibitory Concentration (IC50) 5020 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[42]
Half Maximal Inhibitory Concentration (IC50) 5200 nM
J774 cells
Mouse reticulum cell sarcoma
CVCL_4692 
[80]
Half Maximal Effective Concentration (EC50) 55 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 5500 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[81]
Half Maximal Inhibitory Concentration (IC50) 580 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[82]
Half Maximal Effective Concentration (EC50) 6.1 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 6.31 nM
INS-1 832/13 cells
Rat insulinoma
CVCL_7226 
[24]
Half Maximal Inhibitory Concentration (IC50) 6.4 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [52]
Half Maximal Inhibitory Concentration (IC50) 6.5 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[3]
Half Maximal Effective Concentration (EC50) 6.7 nM
Reh cells
B acute lymphoblastic leukemia
CVCL_1650 
[83]
Half Maximal Inhibitory Concentration (IC50) 6000 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[84]
Half Maximal Inhibitory Concentration (IC50) 6100 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[84]
Half Maximal Inhibitory Concentration (IC50) 630 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[85]
Half Maximal Inhibitory Concentration (IC50) 630 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[86]
Half Maximal Effective Concentration (EC50) 66 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 6900 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[87]
Half Maximal Inhibitory Concentration (IC50) 7 nM
THP-1 cells
Childhood acute monocytic leukemia
CVCL_0006 
[30]
Half Maximal Effective Concentration (EC50) 7.2 nM
COS-7 cells
Normal
CVCL_0224 
[88]
Half Maximal Effective Concentration (EC50) 7.6 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Effective Concentration (EC50) 7.943 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[20]
Half Maximal Effective Concentration (EC50) 7.943 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[52]
Half Maximal Inhibitory Concentration (IC50) 7.943 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[21]
Half Maximal Inhibitory Concentration (IC50) 700 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[89]
Half Maximal Inhibitory Concentration (IC50) 7000 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[90]
Half Maximal Effective Concentration (EC50) 72 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 74 nM
N9 cells
Normal
Undisclosed [72]
Half Maximal Inhibitory Concentration (IC50) 7900 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[91]
Half Maximal Inhibitory Concentration (IC50) 7900 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[92]
Half Maximal Inhibitory Concentration (IC50) 8 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [51]
Half Maximal Inhibitory Concentration (IC50) 8.06 nM
HeLa S3 cells
Endocervical adenocarcinoma
CVCL_0058 
[93]
Half Maximal Inhibitory Concentration (IC50) 800 nM
B-cells
Normal
Undisclosed [43]
Half Maximal Inhibitory Concentration (IC50) 800 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[26]
Half Maximal Inhibitory Concentration (IC50) 800 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[94]
Half Maximal Inhibitory Concentration (IC50) 800 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[95]
Half Maximal Inhibitory Concentration (IC50) 800 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[96]
Half Maximal Effective Concentration (EC50) 82 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 8280 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[97]
Half Maximal Inhibitory Concentration (IC50) 8300 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[98]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 83560.3 nM
EKVX cells
Non-small cell lung carcinoma
CVCL_1195 
[25]
Half Maximal Inhibitory Concentration (IC50) 8400 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[84]
Half Maximal Inhibitory Concentration (IC50) 860 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[99]
Half Maximal Inhibitory Concentration (IC50) 8700 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[100]
Half Maximal Inhibitory Concentration (IC50) 8710 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[73]
Half Maximal Effective Concentration (EC50) 88 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 9 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [51]
Half Maximal Effective Concentration (EC50) 9.4 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [4]
Half Maximal Inhibitory Concentration (IC50) 9.5 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [47]
Half Maximal Inhibitory Concentration (IC50) 920 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[101]
Half Maximal Inhibitory Concentration (IC50) 9400 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[33]
Half Maximal Inhibitory Concentration (IC50) 9500 nM
BV-2 cells
Normal
CVCL_0182 
[102]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 95060.48 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 95940.06 nM
DMS 114 cells
Lung small cell carcinoma
CVCL_1174 
[25]
Half Maximal Inhibitory Concentration (IC50) 980 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[103]
Each Antibody-drug Conjugate Related to This Payload
References
Ref 1 Oleanolic acid analogs as NO, TNF- and IL-1 inhibitors: synthesis, biological evaluation and docking studies. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4114-9. doi: 10.1016/j.bmcl.2014.07.056. Epub 2014 Jul 25.
Ref 2 A new antimalarial quassinoid from Simaba orinocensis. J Nat Prod. 2004 May;67(5):772-7. doi: 10.1021/np030524n.
Ref 3 Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma. J Med Chem. 2007 Sep 20;50(19):4699-709. doi: 10.1021/jm070370z. Epub 2007 Aug 17.
Ref 4 Macrolactonolides: a novel class of anti-inflammatory compounds. Bioorg Med Chem. 2013 Jan 1;21(1):321-32. doi: 10.1016/j.bmc.2012.10.036. Epub 2012 Oct 30.
Ref 5 Identification of dissociated non-steroidal glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2007 Sep 15;17(18):5025-31. doi: 10.1016/j.bmcl.2007.07.031. Epub 2007 Jul 25.
Ref 6 Synthesis and biochemical characterization of a series of 17-perfluoroalkylated estradiols as selective ligands for estrogen receptor . J Med Chem. 2010 Oct 14;53(19):6947-53. doi: 10.1021/jm100563h.
Ref 7 Sundaicumones A and B, polyprenylated acylphloroglucinol derivatives from Calophyllumsundaicum with weak activity against the glucocorticoid receptor. J Nat Prod. 2006 Apr;69(4):707-9. doi: 10.1021/np050528n.
Ref 8 Non-steroidal glucocorticoid agonists: the discovery of aryl pyrazoles as A-ring mimetics. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4737-45. doi: 10.1016/j.bmcl.2007.06.066. Epub 2007 Jun 26.
Ref 9 Highly tractable, sub-nanomolar non-steroidal glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4846-50. doi: 10.1016/j.bmcl.2009.06.020. Epub 2009 Jun 13.
Ref 10 Discovery of a potent series of non-steroidal non -trifluoromethyl carbinol glucocorticoid receptor agonists with reduced lipophilicity. Bioorg Med Chem Lett. 2011 Feb 15;21(4):1126-33. doi: 10.1016/j.bmcl.2010.12.121. Epub 2010 Dec 31.
Ref 11 Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate. ACS Med Chem Lett. 2014 Nov 20;5(12):1318-23. doi: 10.1021/ml500387y. eCollection 2014 Dec 11.
Ref 12 Structural design, synthesis and substituent effect of hydrazone-N-acylhydrazones reveal potent immunomodulatory agents. Bioorg Med Chem. 2018 May 1;26(8):1971-1985. doi: 10.1016/j.bmc.2018.02.047. Epub 2018 Feb 25.
Ref 13 Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2139-43. doi: 10.1016/j.bmcl.2009.03.006. Epub 2009 Mar 9.
Ref 14 Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators. J Med Chem. 2010 Feb 11;53(3):1270-80. doi: 10.1021/jm901551w.
Ref 15 Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists. J Med Chem. 2010 Dec 9;53(23):8241-51. doi: 10.1021/jm100957a. Epub 2010 Nov 12.
Ref 16 Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5448-51. doi: 10.1016/j.bmcl.2013.06.085. Epub 2013 Jul 4.
Ref 17 Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series. J Med Chem. 2006 Jul 13;49(14):4216-31. doi: 10.1021/jm060302x.
Ref 18 Stereoisomers of an Aryl Pyrazole Glucocorticoid Receptor Agonist Scaffold Elicit Differing Anti-inflammatory Responses. ACS Med Chem Lett. 2022 Aug 22;13(9):1493-1499. doi: 10.1021/acsmedchemlett.2c00299. eCollection 2022 Sep 8.
Ref 19 Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for ROR and RORt. Bioorg Med Chem Lett. 2014 Nov 15;24(22):5265-7. doi: 10.1016/j.bmcl.2014.09.053. Epub 2014 Sep 28.
Ref 20 Discovery of quinolines as selective glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5835-8. doi: 10.1016/j.bmcl.2010.07.125. Epub 2010 Aug 3.
Ref 21 Discovery of new selective glucocorticoid receptor agonist leads. Bioorg Med Chem Lett. 2017 Feb 1;27(3):437-442. doi: 10.1016/j.bmcl.2016.12.047. Epub 2016 Dec 23.
Ref 22 2-Aryl-3-methyloctahydrophenanthrene-2,3,7-triols as potent dissociated glucocorticoid receptor agonists. J Med Chem. 2015 Mar 26;58(6):2658-77. doi: 10.1021/jm501601b. Epub 2015 Mar 17.
Ref 23 Quinol-4-ones as steroid A-ring mimetics in nonsteroidal dissociated glucocorticoid agonists. J Med Chem. 2006 Dec 28;49(26):7887-96. doi: 10.1021/jm061273t.
Ref 24 Potent Anti-Inflammatory, Arylpyrazole-Based Glucocorticoid Receptor Agonists That Do Not Impair Insulin Secretion. ACS Med Chem Lett. 2021 Sep 15;12(10):1568-1577. doi: 10.1021/acsmedchemlett.1c00379. eCollection 2021 Oct 14.
Ref 25 PubChem BioAssay data set.
Ref 26 A new ursane-type triterpenoid glycoside from Centella asiatica leaves modulates the production of nitric oxide and secretion of TNF- in activated RAW 264.7 cells. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1777-81. doi: 10.1016/j.bmcl.2011.01.066. Epub 2011 Jan 22.
Ref 27 Anti-inflammatory Potential of Saponins from Aster tataricus via NF-B/MAPK Activation. J Nat Prod. 2019 May 24;82(5):1139-1148. doi: 10.1021/acs.jnatprod.8b00856. Epub 2019 Apr 1.
Ref 28 Bioactive triterpene glycosides from the fruit of Stauntonia hexaphylla and insights into the molecular mechanism of its inflammatory effects. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2085-2089. doi: 10.1016/j.bmcl.2019.07.010. Epub 2019 Jul 6.
Ref 29 Design and synthesis of new nonsteroidal glucocorticoid modulators through application of an "agreement docking" method. J Med Chem. 2005 Jul 14;48(14):4507-10. doi: 10.1021/jm050345y.
Ref 30 Synthesis and evaluation of pyrazolo[3,4-b]pyridines and its structural analogues as TNF-alpha and IL-6 inhibitors. Bioorg Med Chem. 2008 Aug 1;16(15):7167-76. doi: 10.1016/j.bmc.2008.06.042. Epub 2008 Jun 26.
Ref 31 Withaferin A induces cell death and differentiation in multiple myeloma cancer stem cells. Medchemcomm. 2016 Nov 17;8(1):112-121. doi: 10.1039/c6md00410e. eCollection 2017 Jan 1.
Ref 32 Nitric Oxide Inhibitory Sesquiterpenoids and Its Dimers from Artemisia freyniana. J Nat Prod. 2018 Apr 27;81(4):866-878. doi: 10.1021/acs.jnatprod.7b00947. Epub 2018 Mar 8.
Ref 33 Leucoflavonine, a new bioactive racemic flavoalkaloid from the leaves of Leucosceptrum canum. Bioorg Med Chem. 2019 Jan 15;27(2):442-446. doi: 10.1016/j.bmc.2018.12.023. Epub 2018 Dec 16.
Ref 34 Isolation, structural elucidation, and insights into the anti-inflammatory effects of triterpene saponins from the leaves of Stauntonia hexaphylla. Bioorg Med Chem Lett. 2019 Apr 15;29(8):965-969. doi: 10.1016/j.bmcl.2019.02.022. Epub 2019 Feb 21.
Ref 35 Anti-inflammatory phenylpropanoid glycosides from the fruits of Forsythia suspensa. Bioorg Med Chem Lett. 2019 Oct 1;29(19):126635. doi: 10.1016/j.bmcl.2019.126635. Epub 2019 Aug 23.
Ref 36 In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos. 2012 Jan;40(1):130-8. doi: 10.1124/dmd.111.040758. Epub 2011 Sep 30.
Ref 37 Discovery of a potential anti-inflammatory agent: 3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile. J Med Chem. 2013 Mar 14;56(5):1984-95. doi: 10.1021/jm301652t. Epub 2013 Feb 27.
Ref 38 Discovery of novel 3-hydroxyandrosta-5,7-Diene-17-Carboxylic acid derivatives as anti-inflammatory bowel diseases (IBD) agents. Eur J Med Chem. 2021 Aug 5;220:113468. doi: 10.1016/j.ejmech.2021.113468. Epub 2021 Apr 24.
Ref 39 Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators. Bioorg Med Chem Lett. 2019 Sep 1;29(17):2443-2447. doi: 10.1016/j.bmcl.2019.07.035. Epub 2019 Jul 23.
Ref 40 Cationic lipid-conjugated dexamethasone as a selective antitumor agent. Eur J Med Chem. 2014 Aug 18;83:433-47. doi: 10.1016/j.ejmech.2014.06.051. Epub 2014 Jun 25.
Ref 41 Three-component synthesis of chromeno -lactam hybrids for inflammation and cancer screening. Eur J Med Chem. 2019 Oct 1;179:389-403. doi: 10.1016/j.ejmech.2019.06.036. Epub 2019 Jun 17.
Ref 42 Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds. Eur J Med Chem. 2022 Aug 5;238:114438. doi: 10.1016/j.ejmech.2022.114438. Epub 2022 May 6.
Ref 43 Immunosuppressive Nor-isopimarane Diterpenes from Cultures of the Fungicolous Fungus Xylaria longipes HFG1018. J Nat Prod. 2020 Feb 28;83(2):401-412. doi: 10.1021/acs.jnatprod.9b00889. Epub 2020 Jan 21.
Ref 44 Siphonols A-E: novel nitric oxide inhibitors from Orthosiphon stamineus of Indonesia. Bioorg Med Chem Lett. 2003 Jan 6;13(1):31-5. doi: 10.1016/s0960-894x(02)00854-5.
Ref 45 Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6842-51. doi: 10.1016/j.bmcl.2011.09.018. Epub 2011 Sep 10.
Ref 46 Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore. Bioorg Med Chem Lett. 2014 Apr 15;24(8):1934-40. doi: 10.1016/j.bmcl.2014.03.005. Epub 2014 Mar 12.
Ref 47 Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1680-3. doi: 10.1016/j.bmcl.2013.01.072. Epub 2013 Jan 29.
Ref 48 Nitric oxide inhibitory isopimarane-type diterpenes from Orthosiphon stamineus of Indonesia. J Nat Prod. 2003 Feb;66(2):255-8. doi: 10.1021/np020455x.
Ref 49 Colletopeptides A-D, Anti-inflammatory Cyclic Tridepsipeptides from the Plant Endophytic Fungus Colletotrichum sp. S8. J Nat Prod. 2019 Jun 28;82(6):1434-1441. doi: 10.1021/acs.jnatprod.8b00829. Epub 2019 Jun 4.
Ref 50 Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity.
Ref 51 Anti-inflammatory diterpenoids from the root bark of Acanthopanax gracilistylus. J Nat Prod. 2014 Nov 26;77(11):2342-51. doi: 10.1021/np500125x. Epub 2014 Oct 22.
Ref 52 Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate. Bioorg Med Chem Lett. 2020 Aug 15;30(16):127298. doi: 10.1016/j.bmcl.2020.127298. Epub 2020 Jun 1.
Ref 53 Heterocyclic glucocorticoid receptor modulators with a 2,2-dimethyl-3-phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5571-4. doi: 10.1016/j.bmcl.2013.08.049. Epub 2013 Aug 16.
Ref 54 Acid-catalyzed synthesis of 10-substituted triazolyl artemisinins and their growth inhibitory activity against various cancer cells. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4112-5. doi: 10.1016/j.bmcl.2010.05.074. Epub 2010 Jun 9.
Ref 55 Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents. J Med Chem. 2007 Apr 19;50(8):1731-4. doi: 10.1021/jm070141c. Epub 2007 Mar 17.
Ref 56 Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents. J Med Chem. 2011 Mar 24;54(6):1762-78. doi: 10.1021/jm101445p. Epub 2011 Mar 1.
Ref 57 2'-Hydroxy flavanone derivatives as an inhibitors of pro-inflammatory mediators: Experimental and molecular docking studies. Bioorg Med Chem Lett. 2015 May 1;25(9):1952-5. doi: 10.1016/j.bmcl.2015.03.025. Epub 2015 Mar 14.
Ref 58 Anti-inflammatory Dimeric Benzophenones from an Endophytic Pleosporales Species. J Nat Prod. 2022 Jan 28;85(1):162-168. doi: 10.1021/acs.jnatprod.1c00900. Epub 2022 Jan 10.
Ref 59 Structurally Diverse Labdane Diterpenoids from Leonurus japonicus and Their Anti-inflammatory Properties in LPS-Induced RAW264.7 Cells. J Nat Prod. 2020 Sep 25;83(9):2545-2558. doi: 10.1021/acs.jnatprod.9b00597. Epub 2020 Sep 16.
Ref 60 Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. J Nat Prod. 2015 Jul 24;78(7):1526-35. doi: 10.1021/np500951s. Epub 2015 Jun 25.
Ref 61 Ochracenes A-I, Humulane-Derived Sesquiterpenoids from the Antarctic Fungus Aspergillus ochraceopetaliformis. J Nat Prod. 2017 Jun 23;80(6):1725-1733. doi: 10.1021/acs.jnatprod.6b00810. Epub 2017 Jun 9.
Ref 62 Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos. 2011 Jan;39(1):151-9. doi: 10.1124/dmd.110.035105. Epub 2010 Oct 21.
Ref 63 Strigolactones: a plant phytohormone as novel anti-inflammatory agents. Medchemcomm. 2017 Dec 5;9(1):181-188. doi: 10.1039/c7md00461c. eCollection 2018 Jan 1.
Ref 64 New naphtho/thienobenzo-triazoles with interconnected anti-inflammatory and cholinesterase inhibitory activity. Eur J Med Chem. 2022 Nov 5;241:114616. doi: 10.1016/j.ejmech.2022.114616. Epub 2022 Jul 19.
Ref 65 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents. Bioorg Med Chem. 2016 Apr 15;24(8):1793-810. doi: 10.1016/j.bmc.2016.03.006. Epub 2016 Mar 3.
Ref 66 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH(3) or 2-CH(3). Bioorg Med Chem. 2017 Jan 15;25(2):471-482. doi: 10.1016/j.bmc.2016.11.014. Epub 2016 Nov 11.
Ref 67 Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2022 Jul 28;65(14):9974-10000. doi: 10.1021/acs.jmedchem.2c00641. Epub 2022 Jul 7.
Ref 68 Diarylheptanoids with NO production inhibitory activity from Amomum kravanh. Bioorg Med Chem Lett. 2020 Apr 15;30(8):127026. doi: 10.1016/j.bmcl.2020.127026. Epub 2020 Feb 13.
Ref 69 Phenolic and iridoid glycosides from the rhizomes of Cyperus rotundus L[J]. Medicinal Chemistry Research, 2013, 22: 4830-4835.
Ref 70 Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1834-8. doi: 10.1016/j.bmcl.2013.01.025. Epub 2013 Jan 16.
Ref 71 Synthesis and evaluation of 1,2,4-oxadiazole derivatives as potential anti-inflammatory agents by inhibiting NF-B signaling pathway in LPS-stimulated RAW 264.7 cells. Bioorg Med Chem Lett. 2020 Sep 1;30(17):127373. doi: 10.1016/j.bmcl.2020.127373. Epub 2020 Jul 11.
Ref 72 Synthesis and antiinflammatory evaluation of 9-anilinoacridine and 9-phenoxyacridine derivatives. J Med Chem. 2002 Oct 10;45(21):4689-94. doi: 10.1021/jm020102v.
Ref 73 Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. Eur J Med Chem. 2021 Mar 5;213:113174. doi: 10.1016/j.ejmech.2021.113174. Epub 2021 Jan 20.
Ref 74 Terpenoids from Chloranthus serratus and their anti-inflammatory activities. J Nat Prod. 2012 Apr 27;75(4):694-8. doi: 10.1021/np200968p. Epub 2012 Feb 28.
Ref 75 Syntheses of immunomodulating androstanes and stigmastanes: comparison of their TNF-alpha inhibitory activity. Bioorg Med Chem. 2007 Dec 15;15(24):7538-44. doi: 10.1016/j.bmc.2007.09.012. Epub 2007 Sep 14.
Ref 76 Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation. Bioorg Med Chem Lett. 2001 Feb 26;11(4):545-8. doi: 10.1016/s0960-894x(00)00718-6.
Ref 77 Alkaloids from the Australian rainforest tree Ochrosia moorei. J Nat Prod. 2008 Jun;71(6):1063-5. doi: 10.1021/np070655e. Epub 2008 Apr 16.
Ref 78 Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. doi: 10.1021/jm021012t.
Ref 79 Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013 Feb 14;56(3):781-795. doi: 10.1021/jm301302s. Epub 2013 Jan 22.
Ref 80 Bioactive Compounds from the Aerial Parts of Evolvulus linarioides. J Nat Prod. 2020 May 22;83(5):1515-1523. doi: 10.1021/acs.jnatprod.9b01189. Epub 2020 May 4.
Ref 81 Isopimarane Diterpenoids from the Rhizomes of Kaempferia marginata and Their Potential Anti-inflammatory Activities. J Nat Prod. 2020 Jan 24;83(1):14-19. doi: 10.1021/acs.jnatprod.9b00307. Epub 2019 Dec 24.
Ref 82 Anti-inflammatory Cassane-Type Diterpenoids from the Seed Kernels of Caesalpinia sinensis. J Nat Prod. 2021 Aug 27;84(8):2175-2188. doi: 10.1021/acs.jnatprod.1c00233. Epub 2021 Aug 1.
Ref 83 Deacylcortivazol-like pyrazole regioisomers reveal a more accommodating expanded binding pocket for the glucocorticoid receptor. RSC Med Chem. 2020 Dec 8;12(2):203-212. doi: 10.1039/d0md00278j. eCollection 2021 Mar 4.
Ref 84 Anti-inflammatory Chalcone-Isoflavone Dimers and Chalcone Dimers from Caragana jubata. J Nat Prod. 2019 Oct 25;82(10):2761-2767. doi: 10.1021/acs.jnatprod.9b00365. Epub 2019 Oct 2.
Ref 85 Neolignans with a Rare 2-Oxaspiro[4.5]deca-6,9-dien-8-one Motif from the Stem Bark of Cinnamomum subavenium. J Nat Prod. 2015 Jul 24;78(7):1740-4. doi: 10.1021/np5010533. Epub 2015 Jun 18.
Ref 86 Flavans with potential anti-inflammatory activities from Zephyranthes candida. Bioorg Med Chem Lett. 2016 Dec 15;26(24):5967-5970. doi: 10.1016/j.bmcl.2016.10.081. Epub 2016 Oct 28.
Ref 87 Longipetalol A: A Highly Modified Triterpenoid from Dichapetalum longipetalum. J Nat Prod. 2021 May 28;84(5):1556-1562. doi: 10.1021/acs.jnatprod.1c00068. Epub 2021 Apr 29.
Ref 88 The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144. J Nat Prod. 2009 Nov;72(11):1944-8. doi: 10.1021/np9004882.
Ref 89 Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages. J Nat Prod. 2002 Mar;65(3):379-81. doi: 10.1021/np0101651.
Ref 90 Alkaloids from aerial parts of Houttuynia cordata and their anti-inflammatory activity. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2807-2811. doi: 10.1016/j.bmcl.2017.04.072. Epub 2017 Apr 26.
Ref 91 Anti-inflammatory Lathyrane Diterpenoids from Euphorbia lathyris. J Nat Prod. 2019 Apr 26;82(4):756-764. doi: 10.1021/acs.jnatprod.8b00600. Epub 2019 Feb 28.
Ref 92 Synthesis of lathyrane diterpenoid nitrogen-containing heterocyclic derivatives and evaluation of their anti-inflammatory activities. Bioorg Med Chem. 2022 Feb 15;56:116627. doi: 10.1016/j.bmc.2022.116627. Epub 2022 Jan 14.
Ref 93 DrugMatrix in vitro pharmacology data.
Ref 94 New ent-kauranes from the fruits of Annona glabra and their inhibitory nitric oxide production in LPS-stimulated RAW264.7 macrophages. Bioorg Med Chem Lett. 2015 Jan 15;25(2):254-8. doi: 10.1016/j.bmcl.2014.11.059. Epub 2014 Nov 27.
Ref 95 ()-Acortatarinowins A-F, Norlignan, Neolignan, and Lignan Enantiomers from Acorus tatarinowii. J Nat Prod. 2015 Sep 25;78(9):2205-14. doi: 10.1021/acs.jnatprod.5b00328. Epub 2015 Aug 25.
Ref 96 Anti-inflammatory Grayanane Diterpenoids from the Leaves of Rhododendron molle. J Nat Prod. 2018 Jan 26;81(1):151-161. doi: 10.1021/acs.jnatprod.7b00799. Epub 2017 Dec 22.
Ref 97 Structural Elucidation of Garcipaucinones A and B From Garcinia paucinervis Using Quantum Chemical Calculations. J Nat Prod. 2021 Apr 23;84(4):972-978. doi: 10.1021/acs.jnatprod.0c00883. Epub 2021 Mar 5.
Ref 98 Structures and Biological Evaluation of Monoterpenoid Glycosides from the Roots of Paeonia lactiflora. J Nat Prod. 2018 May 25;81(5):1252-1259. doi: 10.1021/acs.jnatprod.8b00087. Epub 2018 May 9.
Ref 99 Chisopanins A-K, 11 new protolimonoids from Chisocheton paniculatus and their anti-inflammatory activities. Bioorg Med Chem. 2011 Feb 15;19(4):1409-17. doi: 10.1016/j.bmc.2011.01.007. Epub 2011 Jan 11.
Ref 100 Bioactive polyoxygenated cembranoids from a novel Hainan chemotype of the soft coral Sinularia flexibilis. Bioorg Med Chem Lett. 2019 Jan 15;29(2):185-188. doi: 10.1016/j.bmcl.2018.12.004. Epub 2018 Dec 3.
Ref 101 Design and development of 1,3,5-triazine derivatives as protective agent against spinal cord injury in rat via inhibition of NF-?B. Bioorg Med Chem Lett. 2021 Jun 1;41:127964. doi: 10.1016/j.bmcl.2021.127964. Epub 2021 Mar 17.
Ref 102 Anti-inflammatory isoflavones and isoflavanones from the roots of Pongamia pinnata (L.) Pierre. Bioorg Med Chem Lett. 2018 Apr 1;28(6):1050-1055. doi: 10.1016/j.bmcl.2018.02.026. Epub 2018 Feb 15.
Ref 103 Cytotoxic and anti-inflammatory triterpenoids from Toona ciliata. J Nat Prod. 2012 Apr 27;75(4):538-46. doi: 10.1021/np200579b. Epub 2012 Mar 9.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.